Agios Pharmaceuticals Newsroom

Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $55

Moomoo NewsJul 23 07:31 ET

Agios Pharmaceuticals Analyst Ratings

BenzingaJun 13 17:08 ET

Agios Pharmaceuticals Analyst Ratings

BenzingaJun 4 09:33 ET

Agios Pharmaceuticals Analyst Ratings

BenzingaMay 3 11:50 ET

Agios Pharmaceuticals Analyst Ratings

BenzingaApr 9 08:27 ET

Agios Pharmaceuticals Analyst Ratings

BenzingaFeb 23 12:33 ET

Agios Pharmaceuticals Analyst Ratings

BenzingaFeb 16 11:55 ET

RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating

MT NewswiresFeb 16 07:52 ET

Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $28

BenzingaNov 3, 2023 10:18 ET

Agios Pharmaceuticals Analyst Ratings

BenzingaNov 3, 2023 10:15 ET

JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $32

BenzingaAug 7, 2023 11:43 ET

Agios Pharmaceuticals Analyst Ratings

BenzingaAug 7, 2023 11:42 ET

RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $42

BenzingaJun 27, 2023 07:43 ET

RBC Lifts Price Target on Agios Pharmaceuticals to $42 From $40 as Phase 2 Trial of Sickle Cell Disease Treatment Meets Primary Endpoint; Outperform Kept

MT NewswiresJun 27, 2023 07:18 ET

Piper Sandler Initiates Coverage On Agios Pharmaceuticals With Overweight Rating, Announces Price Target of $41

Benzinga Real-time NewsFeb 3, 2023 05:03 ET

JPMorgan Chase Adjusts Price Target on Agios Pharmaceuticals to $33 From $48, Maintains Neutral Rating

MT NewswiresDec 1, 2022 09:42 ET

Agios Pharmaceuticals Upgraded to Neutral at Goldman Sachs on Pyrukynd Outlook

Seeking AlphaNov 17, 2022 11:37 ET

Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral, Raises Price Target to $32

Benzinga Real-time NewsNov 17, 2022 08:26 ET

RBC Trims Price Target on Agios Pharmaceuticals to $43 From $44, Maintains Outperform Rating

MT NewswiresNov 4, 2022 08:19 ET

Agios Pharmaceuticals Is Maintained at Outperform by SVB Leerink

Dow JonesAug 5, 2022 12:47 ET